Loading
Led the GD2 CAR-T trial in diffuse midline glioma and defined antigen density as a barrier to CAR-T in solid tumours.
Robbie Majzner was first author of the Nature trial of GD2-directed CAR T cells in H3K27M-mutant diffuse midline glioma, one of the first cell therapies to show activity in a paediatric brain tumour, and led the work showing CAR T cells need high antigen density and that B7-H3 is a broadly expressed paediatric target. He moved from Stanford to lead solid tumour immunotherapy at St. Jude.
| Title | Journal | Year |
|---|---|---|
| GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas | Nature | 2022 |
| Tuning the antigen density requirement for CAR T-cell activity | Cancer Discovery | 2020 |
Shares CAR-T cell therapy and the tags cell-therapy, car-t, paediatric.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CAR-T cell therapy and the tags cell-therapy, paediatric.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares CAR-T cell therapy and the tags cell-therapy, car-t.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares CAR-T cell therapy and the tags car-t, paediatric.